(NASDAQ: MDXG) Mimedx Group's forecast annual revenue growth rate of 5.43% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 294.78%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.91%.
Mimedx Group's revenue in 2025 is $393,442,000.On average, 7 Wall Street analysts forecast MDXG's revenue for 2025 to be $61,490,535,395, with the lowest MDXG revenue forecast at $58,056,046,328, and the highest MDXG revenue forecast at $64,302,995,395. On average, 7 Wall Street analysts forecast MDXG's revenue for 2026 to be $62,940,455,532, with the lowest MDXG revenue forecast at $59,086,837,355, and the highest MDXG revenue forecast at $66,992,530,602.
In 2027, MDXG is forecast to generate $70,252,259,122 in revenue, with the lowest revenue forecast at $64,993,151,456 and the highest revenue forecast at $75,001,895,361.